Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma

Amsterdam UMC Cancer Center Amsterdam researchers Jacqueline Cloos (department of hematology) and Elisa Giovannetti (laboratory medical oncology) and their teams have published a paper in EBioMedicine, a new journal for translational biomedical research published by The Lancet. Leading an international collaboration with researchers from US and Italy, they investigated splicing modulation (a process by which a new gene
can be made using multiple proteins with different functions) both as molecular prognostic factor and potential novel target in diffuse malignant peritoneal mesothelioma (DMPM). Elisa Giovannetti: “DPMP is a rare disease characterized by poor survival rates and refractoriness to current
therapeutic regimes, thus novel therapeutic approaches are urgently needed. Our clinical data enrich the current understanding of DMPM pathobiology and assign new prognostic roles to SF3B1, which prompt validation studies and may be extended to other spliceosome components. Also, our in vitro
and in vivo efficacy data support the rationale that drugs modulating the spliceosomal activity and its downstream pathways may be applicable to future clinical practice in DMPM
."